Caris Discovery
Unlock Novel Targets for Your Discovery Pipeline
Our goal is to uncover novel solid tumor targets by applying cutting-edge science to our extensive tissue and molecular data repository. Caris Discovery partnerships relentlessly uncover new frontiers of development.
Get Answers from Caris BioPartnering
Caris Discovery Partnering
Caris Discovery partners in three ways, each designed to foster the joint development of novel therapeutics.
Joint Target Discovery
Co-discover new drug targets by leveraging our tissue-based platform with molecular and clinical data
Target Validation
Validate new drug targets with Caris Discovery tools, including IHC and wet lab validation, Caris digitized H&E and IHC slides, and patient survival data
Target Out-License
License existing novel drug targets internally discovered and fully validated by Caris Discovery
Caris Discovery Pipeline
With state of the art in-house wet lab and bioinformatics capabilities, Caris Discovery is building a pipeline of novel oncology targets that seeks to disrupt the bounds of the precision medicine landscape.
| Program | Modality | Target Discovery | Target Validation | In Vivo Proof-of-Concept |
|---|---|---|---|---|
| CARIS-101 | Antibody-Drug Conjugate | |||
| CARIS-201 | Antibody-Drug Conjugate | |||
| CARIS-301 | Antibody-Drug Conjugate | |||
| CARIS-401 | Antibody-Drug Conjugate | |||
| Confidential Oncology Targets | Confidential | |||
PROGRAM
CARIS-101
MODALITY
Antibody-Drug Conjugate
Discovery
Validation
Proof-of-Concept
PROGRAM
CARIS-201
MODALITY
Antibody-Drug Conjugate
Discovery
Validation
Proof-of-Concept
PROGRAM
CARIS-301
MODALITY
Confidential
Discovery
Validation
Proof-of-Concept
PROGRAM
CARIS-401
MODALITY
Confidential
Discovery
Validation
Proof-of-Concept
PROGRAM
Confidential Oncology Targets
MODALITY
Confidential
Discovery
Validation
Proof-of-Concept
Cutting Edge Discovery Engine
The Caris Discovery engine combines advanced science with an unmatched volume of clinically-linked molecular data to uncover novel targets.
Molecular Data-Linked Tissue
Molecular data from more than 500,000 whole exome- and transcriptome-sequenced tissue samples, allows protein expression visualization and semi-quantitative characterization from relevant IHCs.
Proprietary Caris Discovery Platforms
- Proprietary aptamer-based proteomic profiling platform (ADAPT Biotargeting System™)
- Discover new targets in cancer tissue that are masked in other approaches
- Tissue Proximity Labeling
- Identify new bispecific pairs, new targets, and confirm target localization utilizing a known anchor
- Cell Surfaceome for extra-cellular targets
- Confirm cell surface localization and identify targetable epitopes
Longitudinal Outcomes
Longitudinal clinical outcomes data matched to Caris-sequenced samples enables context-driven insights.
Molecular Data
Molecular data from more than 500,000 whole exome- and transcriptome-sequenced tissue samples, allows protein expression visualization and semi-quantitative characterization from relevant IHCs.
Proprietary Caris Discovery Platforms
- Proprietary aptamer-based proteomic profiling platform (ADAPT Biotargeting System™)
- Discover new targets in cancer tissue that are masked in other approaches
- Tissue Proximity Labeling
- Identify new bispecific pairs, new targets, and confirm target localization utilizing a known anchor
- Cell Surfaceome for extra-cellular targets
- Confirm cell surface localization and identify targetable epitopes
Longitudinal Outcomes
Longitudinal clinical outcomes data matched to Caris-sequenced samples enables context-driven insights.
Discover
More
WES & WTS provide assurances to your clinical development programs with data-driven decisions.
Caris Life Sciences is at the forefront of a data-led revolution in personalized cancer care.